Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 25;25(21):4930.
doi: 10.3390/molecules25214930.

A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment

Éamon Jones  1 , Styliani Vlachou  1
Affiliations
Review

A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment

Éamon Jones et al. Molecules. .

Abstract

Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the symptoms associated with the disease. In line with this, Sativex, a synthetic combination of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) has been approved to treat symptoms of spasticity. In animals, CBD is effective in reducing the amounts of T-cell infiltrates in the spinal cord, suggesting CBD has anti-inflammatory properties. By doing this, CBD has shown to delay symptom onset in animal models of multiple sclerosis and slow disease progression. Importantly, combinations of CBD and Δ9-THC appear more effective in treating animal models of multiple sclerosis. While CBD reduces the amounts of cell infiltrates in the spinal cord, Δ9-THC reduces scores of spasticity. In human studies, the results are less encouraging and conflict with the findings in animals. Drugs which deliver a combination of Δ9-THC and CBD in a 1:1 ratio appear to be only moderately effective in reducing spasticity scores, but appear to be almost as effective as current front-line treatments and cause less severe side effects than other treatments, such as baclofen (a GABA-B receptor agonist) and tizanidine (an α2 adrenergic receptor agonist). The findings of the studies reviewed suggest that cannabinoids may help treat neuropathic pain in pwMS as an add-on therapy to already established pain treatments. It is important to note that treatment with cannabinoid compounds may cause significant cognitive dysfunction. Long term double-blind placebo studies are greatly needed to further our understanding of the role of cannabinoids in multiple sclerosis treatment.

Keywords: animal models; cannabidiol; cannabinoid; cognition; experimental autoimmune encephalomyelitis; inflammation; multiple sclerosis; neuropathic pain; neuroprotection; spasticity; Δ9-tetrahydrocannabinol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structure of the two most studied cannabinoid molecules; (a) Δ9-tetrahydrocannabinol, and (b) cannabidiol.
See this image and copyright information in PMC

References

    1. Li H.-L. An archaeological and historical account of cannabis in China. Econ. Bot. 1973;28:437–448. doi: 10.1007/BF02862859. - DOI
    1. Luginbuhl A.M. Industrial Hemp (Cannabis savita L): The Geography of a Controversial Plant. Calif. Geogr. 2001;41:1–14.
    1. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379:55–70. doi: 10.1016/S0140-6736(11)61138-0. - DOI - PubMed
    1. Panagis G., Vlachou S., Nomikos G.G. Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Curr. Drug Abus. Rev. 2008;1:350–374. doi: 10.2174/1874473710801030350. - DOI - PubMed
    1. Panagis G., Mackey B., Vlachou S. Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future. Front. Psychiatry. 2014;5:92. doi: 10.3389/fpsyt.2014.00092. - DOI - PMC - PubMed

MeSH terms